Skip to main content

Table 3 Post-induction and pre-transplantation MRD responses in representative, selected series of adult/elderly Ph+ ALL, by type of TKI and associated induction chemotherapy. The single randomized trial is indicated by an asterisk (*)

From: Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges

Study (author, ref.)

TKI-based therapy

No. of patients with CHR

Post-induction MRD (%)1

CMR

MMR

TKI

Chemotherapy

Daver (2015) [69]

IM

Intensive (Hyper-CVAD)

51

45 (12 weeks)

38 (median 10 weeks)

Pfeifer (2010) [63]

Intensive (GMALL)

247

12.5–33 (consolidation 1)2

–

Chalandon (2015) [68]

Intensive (GRAALL)*

121

9.5 (cycle 1)

28.6 (cycle 2)

43.1 (cycle 1)

66.1 (cycle 2)

Non-intensive (GRAALL)*

133

9.9 (cycle 1)

22.6 (cycle 2)

45.5 (cycle 1)

64.5 (cycle 2)

Vignetti (2007) [79]

None (GIMEMA)3

29

14

–

Ravandi (2015) [72]

DAS

Intensive (Hyper-CVAD)

69

65 (median 4 weeks)

28 (median 4 weeks)

Rousselot (2016) [76]

Non-intensive (EWALL)

67

20 (cycle 1)

24 (cycle 2)

60 (cycle 1)

65 (cycle 2)

Chiaretti (2015) [58]

None (GIMEMA)3

58

18.6

–

Kim (2015) [73]

NIL

Intensive

82

56 (at CHR)

79 (at CHR)

Ottmann (2018) [78]

Non-intensive (EWALL)

68

14 (cycle 1)

58 (consolidation 2)

41 (cycle 1)

86 (consolidation 2)

Chalandon (2018) [77]

Non-intensive (GRAALL)

60

–

80 (cycle 2)

93 (cycle 4)

Papayannidis (2013) [81]

IM/NIL

None (GIMEMA)4

34

35.4 (week 6)

46.6 (week 12)

–

Jabbour (2018) [75]

PON

Intensive (Hyper-CVAD)

76

83 (median 10 weeks)

97 (median 3 weeks)

Martinelli (2017) [83]

None (GIMEMA)3

38

60.6

–

  1. 1Non-standard definitions according to single studies: CMR, complete molecular response (BCR-ABL1 MRD < 0.01–0.001% or undetectable); MMR, major molecular response (BCR-ABL1 MRD < 0.1%); results after treatment course/week/time as indicated
  2. 2IM starting with induction Ib vs. Ia, respectively
  3. 3Plus systemic corticosteroids and intrathecal prophylaxis (methotrexate)
  4. 4Alternating schedule q6 weeks
  5. Abbreviations: IM imatinib, DAS dasatinib, NIL nilotinib, PON ponatinib, CHR complete hematological response, CMR complete molecular response, MMR major molecular response